{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:09:41Z","timestamp":1789427381653,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060078"],"award-info":[{"award-number":["82060078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["Guike AB23026006"],"award-info":[{"award-number":["Guike AB23026006"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project","award":["S2022001"],"award-info":[{"award-number":["S2022001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10495-025-02256-0","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:47:59Z","timestamp":1768232879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progenitor CD8+ T cells and hyper-Treg crosstalk: a driver of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Suning","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2256_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2256_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.48","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P et al (2017) Oesophageal cancer. Nat Rev Dis Primers 3:17048","journal-title":"Nat Rev Dis Primers"},{"key":"2256_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J et al (2022) The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163:649\u201358.e2","journal-title":"Gastroenterology"},{"key":"2256_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-0716-0377-2_5","volume":"2129","author":"R Zhang","year":"2020","unstructured":"Zhang R, Lau LHS, Wu PIC, Yip HC, Wong SH (2020) Endoscopic diagnosis and treatment of esophageal squamous cell carcinoma. Methods Mol Biol 2129:47\u201362","journal-title":"Methods Mol Biol"},{"key":"2256_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102898","author":"H Kurumi","year":"2020","unstructured":"Kurumi H, Isomoto H (2020) Current topics in esophageal squamous cell carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12102898","journal-title":"Cancers (Basel)"},{"key":"2256_CR6","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200898R","volume":"36","author":"K Shi","year":"2022","unstructured":"Shi K, Li Y, Yang L, Zhang Z, Guo D, Zhang J et al (2022) Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing. FASEB J 36:e22620","journal-title":"FASEB J"},{"key":"2256_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728222.2022.2036718","volume":"26","author":"JE Rogers","year":"2022","unstructured":"Rogers JE, Sewastjanow-Silva M, Waters RE, Ajani JA (2022) Esophageal cancer: emerging therapeutics. Expert Opin Ther Targets 26:107\u2013117","journal-title":"Expert Opin Ther Targets"},{"key":"2256_CR8","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1038\/s41467-021-27599-5","volume":"12","author":"HQ Dinh","year":"2021","unstructured":"Dinh HQ, Pan F, Wang G, Huang QF, Olingy CE, Wu ZY et al (2021) Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nat Commun 12:7335","journal-title":"Nat Commun"},{"key":"2256_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310","journal-title":"Immunity"},{"key":"2256_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","volume":"130","author":"JP Ward","year":"2016","unstructured":"Ward JP, Gubin MM, Schreiber RD (2016) The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol 130:25\u201374","journal-title":"Adv Immunol"},{"key":"2256_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J et al (2023) Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci 13:120","journal-title":"Cell Biosci"},{"key":"2256_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577\u2013581","journal-title":"Nature"},{"key":"2256_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571","journal-title":"Nature"},{"key":"2256_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41416-019-0622-3","volume":"122","author":"K Hatogai","year":"2020","unstructured":"Hatogai K, Fujii S, Kitano S, Kojima T, Daiko H, Yoshino T et al (2020) Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma. Br J Cancer 122:413\u2013420","journal-title":"Br J Cancer"},{"key":"2256_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216934","volume":"592","author":"X Zhang","year":"2024","unstructured":"Zhang X, Cui X, Li P, Zhao Y, Ren Y, Zhang H et al (2024) EGC enhances tumor antigen presentation and CD8(+) T cell-mediated antitumor immunity via targeting oncoprotein SND1. Cancer Lett 592:216934","journal-title":"Cancer Lett"},{"key":"2256_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.7150\/thno.65828","volume":"12","author":"J Tu","year":"2022","unstructured":"Tu J, Xu H, Ma L, Li C, Qin W, Chen X et al (2022) Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics 12:747\u2013766","journal-title":"Theranostics"},{"key":"2256_CR17","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1038\/ncomms10582","volume":"7","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR et al (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat Commun 7:10582","journal-title":"Nat Commun"},{"key":"2256_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174027","author":"AL Huff","year":"2023","unstructured":"Huff AL, Longway G, Mitchell JT, Andaloori L, Davis-Marcisak E, Chen F et al (2023) CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.174027","journal-title":"JCI Insight"},{"key":"2256_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122857","author":"HL Kinkead","year":"2018","unstructured":"Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K et al (2018) Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.122857","journal-title":"JCI Insight"},{"key":"2256_CR20","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/s41591-024-02978-9","volume":"30","author":"L Kinget","year":"2024","unstructured":"Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS et al (2024) A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma. Nat Med 30:1667\u20131679","journal-title":"Nat Med"},{"key":"2256_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.766852","volume":"13","author":"J Zhu","year":"2022","unstructured":"Zhu J, Yan M, Yan H, Xu L, Jiang Z, Liao G et al (2022) Single-cell transcriptomic analysis reveals the crosstalk propensity between the tumor intermediate state and the CD8+ T exhausted state to be associated with clinical benefits in melanoma. Front Immunol 13:766852","journal-title":"Front Immunol"},{"key":"2256_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01320-9","volume":"16","author":"G Ji","year":"2024","unstructured":"Ji G, Yang Q, Wang S, Yan X, Ou Q, Gong L et al (2024) Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Med 16:49","journal-title":"Genome Med"},{"key":"2256_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"M De Zuani","year":"2024","unstructured":"De Zuani M, Xue H, Park JS, Dentro SC, Seferbekova Z, Tessier J et al (2024) Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun 15:4388","journal-title":"Nat Commun"},{"issue":"1852\u201370","key":"2256_CR24","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang F et al (2023) Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell 41(1852\u201370):e9","journal-title":"Cancer Cell"},{"key":"2256_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02003-0","volume":"23","author":"JK Park","year":"2024","unstructured":"Park JK, Jeong HO, Kim H, Choi JH, Lee EM, Kim S et al (2024) Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications. Mol Cancer 23:87","journal-title":"Mol Cancer"},{"key":"2256_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12957-024-03435-0","volume":"22","author":"J Cheng","year":"2024","unstructured":"Cheng J, Xiao M, Meng Q, Zhang M, Zhang D, Liu L et al (2024) Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction. World J Surg Oncol 22:156","journal-title":"World J Surg Oncol"},{"key":"2256_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-1949-z","volume":"21","author":"CH Holland","year":"2020","unstructured":"Holland CH, Tanevski J, Perales-Paton J, Gleixner J, Kumar MP, Mereu E et al (2020) Robustness and applicability of transcription factor and pathway analysis tools on single-cell RNA-seq data. Genome Biol 21:36","journal-title":"Genome Biol"},{"key":"2256_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100587","volume":"4","author":"KL Burnham","year":"2024","unstructured":"Burnham KL, Milind N, Lee W, Kwok AJ, Cano-Gamez K, Mi Y et al (2024) eQTLs identify regulatory networks and drivers of variation in the individual response to sepsis. Cell Genom 4:100587","journal-title":"Cell Genom"},{"key":"2256_CR29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","volume":"40","author":"S Salcher","year":"2022","unstructured":"Salcher S, Sturm G, Horvath L, Untergasser G, Kuempers C, Fotakis G et al (2022) High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Cell 40:1503\u201320.e8","journal-title":"Cancer Cell"},{"key":"2256_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00605-w","volume":"12","author":"L Dai","year":"2024","unstructured":"Dai L, Fan G, Xie T, Li L, Tang L, Chen H et al (2024) Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma. Biomark Res 12:58","journal-title":"Biomark Res"},{"key":"2256_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01590-1","volume":"22","author":"P Quan","year":"2024","unstructured":"Quan P, Li X, Si Y, Sun L, Ding FF, Fan Y et al (2024) Single cell analysis reveals the roles and regulatory mechanisms of type-I interferons in Parkinson\u2019s disease. Cell Commun Signal 22:212","journal-title":"Cell Commun Signal"},{"key":"2256_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1288240","volume":"15","author":"K Xu","year":"2024","unstructured":"Xu K, Li D, Qian J, Zhang Y, Zhang M, Zhou H et al (2024) Single-cell disulfidptosis regulator patterns guide intercellular communication of tumor microenvironment that contribute to kidney renal clear cell carcinoma progression and immunotherapy. Front Immunol 15:1288240","journal-title":"Front Immunol"},{"key":"2256_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S et al (2023) Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 78:770\u2013782","journal-title":"J Hepatol"},{"key":"2256_CR34","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2025.2297","author":"N Van Anh","year":"2025","unstructured":"Van Anh N, Gil HW, Park S, Ryu S (2025) Exploring sex differences in type 2 diabetes via a male-dominant beta-cell cluster from single-cell pancreatic sequencing of public datasets. Endocrinol Metab. https:\/\/doi.org\/10.3803\/EnM.2025.2297","journal-title":"Endocrinol Metab"},{"key":"2256_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03858-x","volume":"21","author":"LX Chen","year":"2023","unstructured":"Chen LX, Zeng SJ, Liu XD, Tang HB, Wang JW, Jiang Q (2023) Cell-cell communications shape tumor microenvironment and predict clinical outcomes in clear cell renal carcinoma. J Transl Med 21:113","journal-title":"J Transl Med"},{"key":"2256_CR36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43803","author":"D Kotliar","year":"2019","unstructured":"Kotliar D, Veres A, Nagy MA, Tabrizi S, Hodis E, Melton DA et al (2019) Identifying gene expression programs of cell-type identity and cellular activity with single-cell RNA-Seq. Elife. https:\/\/doi.org\/10.7554\/eLife.43803","journal-title":"Elife"},{"key":"2256_CR37","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/neuonc\/noac085","volume":"24","author":"CP Couturier","year":"2022","unstructured":"Couturier CP, Nadaf J, Li Z, Baig S, Riva G, Le P et al (2022) Glioblastoma scrna-seq shows treatment-induced, immune-dependent increase in mesenchymal cancer cells and structural variants in distal neural stem cells. Neuro Oncol 24:1494\u20131508","journal-title":"Neuro Oncol"},{"key":"2256_CR38","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396\u20131401","journal-title":"Science"},{"key":"2256_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1322147","volume":"14","author":"C Li","year":"2023","unstructured":"Li C, Song W, Zhang J, Luo Y (2023) Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy. Front Immunol 14:1322147","journal-title":"Front Immunol"},{"key":"2256_CR40","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s12276-020-0447-4","volume":"52","author":"JM Murphy","year":"2020","unstructured":"Murphy JM, Rodriguez YAR, Jeong K, Ahn EE, Lim SS (2020) Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med 52:877\u2013886","journal-title":"Exp Mol Med"},{"key":"2256_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6:425","journal-title":"Signal Transduct Target Ther"},{"key":"2256_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X et al (2023) Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer 22:48","journal-title":"Mol Cancer"},{"key":"2256_CR43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s42255-022-00585-x","volume":"4","author":"Z Hu","year":"2022","unstructured":"Hu Z, Zhao TV, Huang T, Ohtsuki S, Jin K, Goronzy IN et al (2022) The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages. Nat Metab 4:759\u2013774","journal-title":"Nat Metab"},{"key":"2256_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD (2020) Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37:443\u2013455","journal-title":"Cancer Cell"},{"key":"2256_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT (2018) Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 118:9\u201316","journal-title":"Br J Cancer"},{"key":"2256_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00014","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F (2018) Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol 9:14","journal-title":"Front Immunol"},{"key":"2256_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, Gogenur I (2021) Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer 124:359\u2013367","journal-title":"Br J Cancer"},{"key":"2256_CR48","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW et al (2019) Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20:326\u2013336","journal-title":"Nat Immunol"},{"key":"2256_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605958","volume":"11","author":"EM Muntjewerff","year":"2020","unstructured":"Muntjewerff EM, Meesters LD, van den Bogaart G, Revelo NH (2020) Reverse signaling by MHC-I molecules in immune and non-immune cell types. Front Immunol 11:605958","journal-title":"Front Immunol"},{"key":"2256_CR50","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM et al (2019) MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574:696\u2013701","journal-title":"Nature"},{"issue":"848\u201361","key":"2256_CR51","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends T, Spanjaard A, Pilzecker B, Babala N, Bovens A, Xiao Y et al (2017) CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 47(848\u201361):e5","journal-title":"Immunity"},{"key":"2256_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar M, Hafler DA (2018) Regulatory T cells in autoimmune disease. Nat Immunol 19:665\u2013673","journal-title":"Nat Immunol"},{"key":"2256_CR53","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Sakaguchi S (2019) Targeting Treg cells in cancer immunotherapy. Eur J Immunol 49:1140\u20131146","journal-title":"Eur J Immunol"},{"key":"2256_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS (2019) T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol 10:2453","journal-title":"Front Immunol"},{"key":"2256_CR55","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y et al (2019) PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 116:9999\u201310008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2256_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105102","volume":"103","author":"M Hashimoto","year":"2024","unstructured":"Hashimoto M, Kojima Y, Sakamoto T, Ozato Y, Nakano Y, Abe T et al (2024) Spatial and single-cell colocalisation analysis reveals MDK-mediated immunosuppressive environment with regulatory T cells in colorectal carcinogenesis. EBioMedicine 103:105102","journal-title":"EBioMedicine"},{"key":"2256_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi4191","volume":"9","author":"MP Plebanek","year":"2024","unstructured":"Plebanek MP, Xue Y, Nguyen YV, DeVito NC, Wang X, Holtzhausen A et al (2024) A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci Immunol 9:eadi4191","journal-title":"Sci Immunol"},{"key":"2256_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084","journal-title":"Front Immunol"},{"key":"2256_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15726-7","volume":"11","author":"JH Lee","year":"2020","unstructured":"Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A et al (2020) Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun 11:1897","journal-title":"Nat Commun"},{"key":"2256_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S et al (2020) Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581:100\u2013105","journal-title":"Nature"},{"key":"2256_CR61","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z et al (2021) Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov 11:1524\u20131541","journal-title":"Cancer Discov"},{"key":"2256_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi CT, Dougan SK (2025) Cytokines in cancer. Cancer Cell 43:15\u201335","journal-title":"Cancer Cell"},{"key":"2256_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S (2025) Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol 25:353\u2013369","journal-title":"Nat Rev Immunol"},{"key":"2256_CR64","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.celrep.2014.09.045","volume":"9","author":"JR Fergusson","year":"2014","unstructured":"Fergusson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R et al (2014) CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep 9:1075\u20131088","journal-title":"Cell Rep"},{"key":"2256_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00214","volume":"5","author":"CL Kirkham","year":"2014","unstructured":"Kirkham CL, Carlyle JR (2014) Complexity and diversity of the NKR-P1:Clr (Klrb1:Clec2) recognition systems. Front Immunol 5:214","journal-title":"Front Immunol"},{"key":"2256_CR66","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","volume":"19","author":"R Gonzalez-Amaro","year":"2013","unstructured":"Gonzalez-Amaro R, Cortes JR, Sanchez-Madrid F, Martin P (2013) Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med 19:625\u2013632","journal-title":"Trends Mol Med"},{"issue":"1281\u201398","key":"2256_CR67","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson ND, Ashenberg O, Tirosh I, Gritsch S, Perez EM, Marx S et al (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184(1281\u201398):e26","journal-title":"Cell"},{"key":"2256_CR68","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/cas.15236","volume":"113","author":"W Di","year":"2022","unstructured":"Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M et al (2022) Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Sci 113:756\u2013769","journal-title":"Cancer Sci"},{"issue":"825\u201341","key":"2256_CR69","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z et al (2020) Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52(825\u201341):e8","journal-title":"Immunity"},{"key":"2256_CR70","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1002\/cam4.5698","volume":"12","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J et al (2023) Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 12:11149\u201311165","journal-title":"Cancer Med"},{"key":"2256_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela NR, Liu S, Zhang Y (2019) Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J 17:1\u201313","journal-title":"Comput Struct Biotechnol J"},{"key":"2256_CR72","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.stem.2024.06.003","volume":"31","author":"PE Saw","year":"2024","unstructured":"Saw PE, Liu Q, Wong PP, Song E (2024) Cancer stem cell mimicry for immune evasion and therapeutic resistance. Cell Stem Cell 31:1101\u20131112","journal-title":"Cell Stem Cell"},{"key":"2256_CR73","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA (2016) CD28 costimulation: from mechanism to therapy. Immunity 44:973\u2013988","journal-title":"Immunity"},{"key":"2256_CR74","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12016-017-8619-2","volume":"54","author":"DEA Komi","year":"2018","unstructured":"Komi DEA, Rambasek T, Wohrl S (2018) Mastocytosis: from a molecular point of view. Clin Rev Allergy Immunol 54:397\u2013411","journal-title":"Clin Rev Allergy Immunol"},{"key":"2256_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061270","author":"JN Lichterman","year":"2021","unstructured":"Lichterman JN, Reddy SM (2021) Mast cells: a new frontier for cancer immunotherapy. Cells. https:\/\/doi.org\/10.3390\/cells10061270","journal-title":"Cells"},{"key":"2256_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061692","author":"R Sulsenti","year":"2023","unstructured":"Sulsenti R, Jachetti E (2023) Frenemies in the microenvironment: harnessing mast cells for cancer immunotherapy. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15061692","journal-title":"Pharmaceutics"},{"key":"2256_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.916137","volume":"13","author":"H Joshi","year":"2022","unstructured":"Joshi H, Morley SC (2022) Efficient T cell migration and activation require L-Plastin. Front Immunol 13:916137","journal-title":"Front Immunol"},{"key":"2256_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040339","author":"C Guerra-Espinosa","year":"2024","unstructured":"Guerra-Espinosa C, Jimenez-Fernandez M, Sanchez-Madrid F, Serrador JM (2024) ICAMs in immunity, intercellular adhesion and communication. Cells. https:\/\/doi.org\/10.3390\/cells13040339","journal-title":"Cells"},{"key":"2256_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00952","volume":"9","author":"BL Walling","year":"2018","unstructured":"Walling BL, Kim M (2018) LFA-1 in T cell migration and differentiation. Front Immunol 9:952","journal-title":"Front Immunol"},{"key":"2256_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02380-z","volume":"23","author":"WB Huang","year":"2025","unstructured":"Huang WB, Lai HZ, Long J, Dai ZL, Ma Q, Xiao C et al (2025) Biomechanics of the tumor extracellular matrix and regulatory T cells: regulatory mechanisms and potential therapeutic targets. Cell Commun Signal 23:375","journal-title":"Cell Commun Signal"},{"key":"2256_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050632","author":"MC Manara","year":"2025","unstructured":"Manara MC, Fiori V, Sparti A, Scotlandi K (2025) CD99: a key regulator in immune response and tumor microenvironment. Biomolecules. https:\/\/doi.org\/10.3390\/biom15050632","journal-title":"Biomolecules"},{"key":"2256_CR82","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont CM, Nelson BH (2023) B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41:466\u2013489","journal-title":"Cancer Cell"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02256-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:02:43Z","timestamp":1774000963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02256-0","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The collection of clinical samples and related experiments were conducted per Guangxi Medical University Cancer Hospital ethics committee, approval number KY20251030.Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"44"}}